首页> 外文期刊>Infection and Drug Resistance >Echinocandins for management of invasive candidiasis in patients with liver disease and liver transplantation
【24h】

Echinocandins for management of invasive candidiasis in patients with liver disease and liver transplantation

机译:棘球and素治疗肝病和肝移植患者侵袭性念珠菌病

获取原文
           

摘要

Candida species remains one of the most important causes of opportunistic infections worldwide. Invasive candidiasis (IC) is associated with considerable morbidity and mortality in liver disease (LD) patients if not treated promptly. Echinocandins are often recommended as a first-line empirical treatment for managing IC and can especially play a critical role in managing IC in LD patients. However, advanced LD patients are often immunocompromised and critically ill. Hence altered pharmacokinetics, drug interactions as well as tolerance issues of antifungal treatments are a concern in these patients. This comprehensive review examines the epidemiology, risk factors and diagnosis of IC in patients with LD and evaluates differences between three available echinocandins for treating this group of patients.
机译:念珠菌仍然是全世界机会性感染的最重要原因之一。如果不及时治疗,侵袭性念珠菌病(IC)与肝病(LD)患者的相当高的发病率和死亡率相关。棘球and素通常被推荐作为管理IC的一线经验疗法,并且在LD患者的IC管理中尤其重要。但是,晚期LD患者通常免疫功能低下且病危。因此,这些患者需要关注药物动力学,药物相互作用以及抗真菌治疗耐受性问题。这项全面的综述检查了LD患者的流行病学,危险因素和IC诊断,并评估了三种可用于治疗该组患者的棘球oc苷之间的差异。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号